Evidence map›Paper›PMID 40827280›Full record

ReviewInternational journal of ophthalmology2025

Advances in treatment of adenoid cystic carcinoma of the lacrimal gland.

Jin-Bei Li, Jian-Min Ma

Abstract readReview
In one paragraph

Review in International journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jin-Bei LiBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Jian-Min MaBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adenoid cystic carcinoma of the lacrimal gland (LGACC) is the most common type of malignant epithelial tumor of the lacrimal gland, which is characterized by a high recurrence rate, perineural invasion, and a propensity to metastasize to distant sites. Due to its unclear pathogenesis, LGACC has a poor prognosis and a high mortality rate. In recent years, a range of radiotherapy and chemotherapy have been clinically applied, leading to a shift in the treatment approach for LGACC. This article discussed the advances being made in the treatment of LGACC and provides readers with an overview of the impact of LGACC treatment modalities on patient survival and prognostic levels.

Indexed as

adenoid cystic carcinomachemotherapylacrimal glandmalignant epithelial tumorradiotherapy

Identifiers

PMID40827280
PMCPMC12311449

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.